- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05745740
Een studie van RC48-ADC in combinatie met pyrotinib voor de behandeling van lokaal gevorderd of gemetastaseerd NSCLC met HER2-mutatie
Een open-label, single-center, fase Ib/II-onderzoek ter evaluatie van de veiligheid, werkzaamheid en farmacokinetiek van RC48-ADC gecombineerd met pyrotinib bij lokaal gevorderd of gemetastaseerd NSCLC met HER2-mutatie
This study will evaluate the efficacy, safety and pharmacokinetics of RC48-ADC for injection combined with pyrotinib in subjects with local advanced or metastatic non-small cell lung cancer with HER2 mutation.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Na Su
- Telefoonnummer: +8610-58075763
- E-mail: na.su@remegen.cn
Studie Contact Back-up
- Naam: Jianmin Fang, Ph.D
- Telefoonnummer: +8610-58075763
- E-mail: jianminfang@hotmail.com
Studie Locaties
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200433
- Shanghai Pulmonary Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Voluntary agreement to provide written informed consent.
- Predicted survival ≥ 12 weeks.
- According to UICC/AJCC 8th Edition, histologically and/or cytologically-confirmed, cannot be surgically removed, locally advanced or metastatic NSCLC.
- Is willing and able to provide an adequate archival tumor tissue sample
- Has relapsed from or is refractory to standard treatment and had received both platinum-based therapy and immunotherapy.
- Measurable lesion according to RECIST 1.1.
- Documented HER2 exon 20 insertion mutation.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Adequate organ function.
- For female subjects: should be surgically sterilized, postmenopausal, or agree to use a medically approved contraceptive (such as an intrauterine device, contraceptives, or condoms) during study treatment and within 6 months after the end of study, the blood pregnancy test within 7 days of study enrollment must be negative and must be non-lactating. Male subjects: Patients who should be surgically sterilized or agree to use a medically approved contraceptive during the study treatment period and within 6 months after the end of the study.
- Willing and able to follow trial and follow-up procedures.
Exclusion Criteria:
- No known EGFR, ALK, ROS1, RET, NTRK, MET 14 or BRAF V600E mutation.
- Patient has had previous treatment with HER2-targeted therapy prior to study participation.
- History of major surgery within 4 weeks of planned start of trial treatment.
- Diagnosed with HBsAg, HBcAb positive and HBV DNA copy positive, or HCVAb positive, or HIVAb positive.
- Has received a live virus vaccine within 4 weeks of planned start of trial treatment.
- NYHA Class III heart failure.
- Suffering from active infection requiring systemic treatment.
- Uncontrolled hypertension, diabetes, Interstitial lung Disease, or COPD.
- Treated with systemic treatment (e.g. immunomodulators, corticosteroids or immunosuppressants) for the autoimmune disease within 2 years prior to the study treatment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: RC48-ADC + Pyrotinib
|
RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
Andere namen:
Pyrotinib 400 mg by oral once a day. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
maximal tolerance dose (MTD) of RC48-ADC combined with Pyrotinib
Tijdsspanne: DLT will be evaluated on 28 days of observation period
|
Maximum-tolerated dose (MTD) was defined as the highest dose level at which no more than one of six patients experienced DLT during the DLT assessment window. |
DLT will be evaluated on 28 days of observation period
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall response rate (ORR)
Tijdsspanne: Up to approximately 3 years
|
The objective response rate will be mainly analyzed by investigators according to the RECIST 1.1 standard tumor evaluation. |
Up to approximately 3 years
|
|
Disease control rate (DCR)
Tijdsspanne: Up to approximately 3 years
|
Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study. |
Up to approximately 3 years
|
|
Duration of relief (DOR)
Tijdsspanne: Up to approximately 3 years
|
DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death. |
Up to approximately 3 years
|
|
Progression-free survival (PFS)
Tijdsspanne: Up to approximately 3 years
|
Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death. |
Up to approximately 3 years
|
|
Overall survival (OS)
Tijdsspanne: Up to approximately 3 years
|
The objective response rate will be mainly analyzed by investigators according to the RECIST 1.1 standard tumor evaluation |
Up to approximately 3 years
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- RC48-C021
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .